Arax Advisory Partners’s Guardant Health GH Stock Holding History

Arax Advisory Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.6K	Sell	462 -271	-37%	-$27.2K	﹤0.01%	1742
2025 Q4	$74.9K	Buy	733 +279	+61%	+$25K	﹤0.01%	1438
2025 Q3	$28.4K	Buy	454 +344	+313%	+$18.7K	﹤0.01%	2111
2025 Q2	$5.72K	Hold	110	–	–	﹤0.01%	2196
2025 Q1	$4.69K	Buy	110 +60	+120%	+$2.59K	﹤0.01%	1804
2024 Q4	$1.53K	Sell	50 -34	-40%	-$956	﹤0.01%	2072
2024 Q3	$1.93K	Hold	84	–	–	﹤0.01%	2077
2024 Q2	$2.43K	Buy	84 +34	+68%	+$792	﹤0.01%	1897
2024 Q1	$1.03K	Sell	50 -50	-50%	-$1.07K	﹤0.01%	1150
2023 Q4	$2.71K	Hold	100	–	–	﹤0.01%	979
2023 Q3	$2.96K	Hold	100	–	–	﹤0.01%	964
2023 Q2	$3.58K	Hold	100	–	–	﹤0.01%	926
2023 Q1	$2.34K	Hold	100	–	–	﹤0.01%	980
2022 Q4	$2.72K	Hold	100	–	–	﹤0.01%	910
2022 Q3	$5K	Hold	100	–	–	﹤0.01%	799
2022 Q2	$4K	Hold	100	–	–	﹤0.01%	824
2022 Q1	$7K	Hold	100	–	–	﹤0.01%	704
2021 Q4	$10K	Hold	100	–	–	﹤0.01%	656
2021 Q3	$13K	Hold	100	–	–	﹤0.01%	605
2021 Q2	$12K	Buy	+100	New	+$13.5K	﹤0.01%	635
2020 Q4	$13K	Hold	100	–	–	﹤0.01%	540
2020 Q3	$11K	Hold	100	–	–	﹤0.01%	530
2020 Q2	$8K	Hold	100	–	–	﹤0.01%	554
2020 Q1	$7K	Buy	+100	New	+$7.67K	﹤0.01%	546

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's GH Position: Q1 2026 in Review

Arax Advisory Partners reduced its Guardant Health (GH) stake by 37% in Q1 2026, selling an estimated $27.2K and leaving 462 shares worth $43.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Arax Advisory Partners first reported a position in GH in Q1 2020 and has held it in 24 quarters since. The position peaked at $74.9K in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Arax Advisory Partners held 462 shares of Guardant Health worth $43.6K as of Q1 2026.
Arax Advisory Partners sold 271 Guardant Health shares in Q1 2026, an estimated $27.2K.
Guardant Health made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1742 holding.
Arax Advisory Partners first reported a position in Guardant Health in Q1 2020 and has held it in 24 quarters since.
Arax Advisory Partners's Guardant Health position peaked at $74.9K in Q4 2025.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.